Brief Title
Long Term Study With B2036-PEG
Official Title
Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
Brief Summary
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
To evaluate the safety and efficacy of long-term B2036-PEG therapy in patients with acromegaly
Secondary Outcome
PK/PD evaluation
Condition
Acromegaly
Intervention
Pegvisomant
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
16
Start Date
April 2004
Completion Date
July 2007
Eligibility Criteria
Inclusion Criteria: - Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009). Exclusion Criteria: - Switching to other therapeutic methods for acromegaly
Gender
All
Ages
20 Years - 75 Years
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, ,
Location Countries
Japan
Location Countries
Japan
Administrative Informations
NCT ID
NCT00143416
Organization ID
A6291011
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
July 2008